TY - JOUR
T1 - Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697
T2 - A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Stage III Non–Small Cell Lung Cancer
AU - Kong, Feng Ming
AU - Hu, Chen
AU - Pryma, Daniel A.
AU - Duan, Fenghai
AU - Matuszak, Martha
AU - Xiao, Ying
AU - Haken, Randall Ten
AU - Siegel, Marilyn J.
AU - Hanna, Lucy
AU - Curran, Walter
AU - Dunphy, Mark
AU - Gelblum, Daphna
AU - Piert, Morand
AU - Jolly, Shruti
AU - Robinson, Clifford G.
AU - Quon, Andrew
AU - Loo, Billy W.
AU - Srinivas, Shyam
AU - Videtic, Gregory M.
AU - Faria, Sergio L.
AU - Ferguson, Catherine
AU - Dunlap, Neal E.
AU - Kundapur, Vijayananda
AU - Paulus, Rebecca
AU - Siegel, Barry A.
AU - Bradley, Jeffrey D.
AU - Machtay, Mitchell
N1 - Publisher Copyright:
© 2024 by American Society of Clinical Oncology.
PY - 2024/11/20
Y1 - 2024/11/20
N2 - PURPOSE NRG-RTOG0617 demonstrated a detrimental effect of uniform high-dose radiation in stage III non–small cell lung cancer. NRG-RTOG1106/ECOGACRIN6697 (ClinicalTrials.gov identifier: NCT01507428), a randomized phase II trial, studied whether midtreatment 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) can guide individualized/ adaptive dose-intensified radiotherapy (RT) to improve and predict outcomes in patients with this disease. MATERIALS Patients fit for concurrent chemoradiation were randomly assigned (1:2) to AND METHODS standard (60 Gy/30 fractions) or FDG-PET–guided adaptive treatment, stratified by substage, primary tumor size, and histology. All patients had midtreatment FDG-PET/CT; adaptive arm patients had an individualized, intensified boost RT dose to residual metabolically active areas. The primary therapeutic end point was 2-year centrally reviewed freedom from local-regional progression (FFLP), defined as no progression in or near the planning target volume and/or regional nodes. FFLP was analyzed on a modified intent-to-treat population at a one-sided Z-test significance level of 0.15. The primary imaging end point was centrally reviewed change in SUVpeak from baseline to midtreatment; its association with FFLP was assessed using the two-sided Wald test on the basis of Cox regression. RESULTS Of 138 patients enrolled, 127 were eligible. Adaptive-arm patients received a mean 71 Gy in 30 fractions, with mean lung dose 17.9 Gy. There was no significant difference in centrally reviewed 2-year FFLP (59.5% and 54.6% in standard and adaptive arms; P 5 .66). There were no significant differences in protocol-specified grade 3 toxicities, survival, or progression-free survival (P > .4). Median SUVpeak and metabolic tumor volume (MTV) in the adaptive arm decreased 49% and 54%, from pre-RT to mid-RT PET. However, DSUVpeak and DMTV were not associated with FFLP (hazard ratios, 0.997; P 5 .395 and .461). CONCLUSION Midtreatment PET-adapted RT dose escalation as given in this study was safe and feasible but did not improve efficacy outcomes.
AB - PURPOSE NRG-RTOG0617 demonstrated a detrimental effect of uniform high-dose radiation in stage III non–small cell lung cancer. NRG-RTOG1106/ECOGACRIN6697 (ClinicalTrials.gov identifier: NCT01507428), a randomized phase II trial, studied whether midtreatment 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) can guide individualized/ adaptive dose-intensified radiotherapy (RT) to improve and predict outcomes in patients with this disease. MATERIALS Patients fit for concurrent chemoradiation were randomly assigned (1:2) to AND METHODS standard (60 Gy/30 fractions) or FDG-PET–guided adaptive treatment, stratified by substage, primary tumor size, and histology. All patients had midtreatment FDG-PET/CT; adaptive arm patients had an individualized, intensified boost RT dose to residual metabolically active areas. The primary therapeutic end point was 2-year centrally reviewed freedom from local-regional progression (FFLP), defined as no progression in or near the planning target volume and/or regional nodes. FFLP was analyzed on a modified intent-to-treat population at a one-sided Z-test significance level of 0.15. The primary imaging end point was centrally reviewed change in SUVpeak from baseline to midtreatment; its association with FFLP was assessed using the two-sided Wald test on the basis of Cox regression. RESULTS Of 138 patients enrolled, 127 were eligible. Adaptive-arm patients received a mean 71 Gy in 30 fractions, with mean lung dose 17.9 Gy. There was no significant difference in centrally reviewed 2-year FFLP (59.5% and 54.6% in standard and adaptive arms; P 5 .66). There were no significant differences in protocol-specified grade 3 toxicities, survival, or progression-free survival (P > .4). Median SUVpeak and metabolic tumor volume (MTV) in the adaptive arm decreased 49% and 54%, from pre-RT to mid-RT PET. However, DSUVpeak and DMTV were not associated with FFLP (hazard ratios, 0.997; P 5 .395 and .461). CONCLUSION Midtreatment PET-adapted RT dose escalation as given in this study was safe and feasible but did not improve efficacy outcomes.
UR - https://www.scopus.com/pages/publications/85206631748
U2 - 10.1200/JCO.24.00022
DO - 10.1200/JCO.24.00022
M3 - Article
C2 - 39365957
AN - SCOPUS:85206631748
SN - 0732-183X
VL - 42
SP - 3935
EP - 3946
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 33
ER -